Course – CloudTable:
Improving Long-Term Outcomes in Exudative Age-Related Macular Degeneration
Course Description “CloudTable: Improving Long-Term Outcomes in Exudative Age-Related Macular Degeneration”
This program is an audio archive of an expert virtual roundtable on improving long-term outcomes in exudative age-related macular degeneration.
As a follow-up to a national expert summit, the Angiogenesis Foundation convened an expert roundtable of leading clinicians to provide an analysis and further reflections on the summit findings. The clinicians were given a synopsis of the expert summit and then asked to provide their insights and contributions on the following topics:
1. Real-world versus clinical trial settings and impact on long-term patient outcomes for anti-VEGF treatments for wet AMD.
2. Variations in care, especially undertreatment, as a barrier to optimal long-term vision outcomes.
3. Actions to improve long-term patient outcomes, including future research using real-world evidence (RWE).
As a supplement to the audio archive, a video animation and an in-depth white paper summarize the expert findings.
Upon completion of this program, clinicians will be able to:
- Understand real-world versus clinical trial settings and impact on long-term patient outcomes for anti-VEGF treatments for wet AMD.
- Discuss variations in care, especially undertreatment, as a barrier to optimal long-term vision outcomes.
- Identify key actions to improve long-term patient outcomes, including future research using real-world evidence (RWE).
Retina specialists, ophthalmologists, clinicians, nurses, health workers, patient advocates, caregivers, and low-vision services providers.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and the Angiogenesis Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.
New York Medical College designates this Enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentations.
William Li, MD
Dr. Li has nothing to disclose with regard to commercial interests.
Mr. Mittman is President of Facilitation, Foresight, Strategy.
Jeffrey McRae, MS
The Angiogenesis Foundation
Mr. McRae has nothing to disclose with regard to commercial interests.
Commercial Support Acknowledgement:
We gratefully acknowledge Regeneron for their generous support of this educational activity.